Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2012



  Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of
  December 31, 2012

  (Pursuant to Article L.233-8 II of the French Commercial Code and articles
   221-1 and 223-16 of the General Regulations of the Autorité des Marchés
                                 Financiers)

Business Wire

CHARENTON-LE-PONT, France -- January 7, 2013

Regulatory News:

As of December 31, 2012, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:

                                                             December 31, 2012
Shares outstanding                                           214,724,040
Exercisable voting rights                                    226,009,144
Total voting rights, based on all outstanding shares,        230,396,621
including shares stripped of their voting rights*

(*) Shares held by the Company, either in treasury or under the liquidity
contract.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates around €150 million to research and development every year,
in a commitment to continuously bring new, more effective products to market.
Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®, Xperio^®,
Optifog™ and Foster Grant^®. It also develops and markets equipment,
instruments and services for eyecare professionals.

Essilor reported consolidated revenue of €4.2 billion in 2011 and employs
around 48,700 people in some 100 countries. It operates 19 plants, a total of
390 prescription laboratories and edging facilities, as well as several
research and development centers around the world.

For more information, please visit

www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the CAC 40 and Euro Stoxx 50 indexes.

Codes and symbols:ISIN:FR0000121667; Reuters:ESSI.PA; Bloomberg:EI:FP.

Contact:

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement